HC Wainwright Analysts Boost Earnings Estimates for Nyxoah

Nyxoah S.A. (NASDAQ:NYXH) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Nyxoah in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will post earnings of ($0.48) per share for the quarter, up from their previous forecast of ($0.50). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Nyxoah’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Nyxoah’s Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Nyxoah (NASDAQ:NYXH) last posted its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $2.02 million.

Separately, Stifel Nicolaus cut their target price on Nyxoah from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, March 14th.

Nyxoah Trading Down 10.2 %

Shares of NYXH stock opened at $8.00 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The company has a market capitalization of $272.48 million, a price-to-earnings ratio of -4.28 and a beta of 1.42. Nyxoah has a 52-week low of $6.76 and a 52-week high of $13.67. The company has a 50-day simple moving average of $10.42 and a two-hundred day simple moving average of $9.34.

Institutional Investors Weigh In On Nyxoah

Several large investors have recently modified their holdings of the stock. Vestal Point Capital LP purchased a new position in shares of Nyxoah in the fourth quarter worth about $23,394,000. Renaissance Technologies LLC purchased a new stake in Nyxoah in the fourth quarter valued at approximately $187,000. Kovack Advisors Inc. lifted its position in Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company’s stock valued at $160,000 after purchasing an additional 10,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after buying an additional 2,774 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in shares of Nyxoah during the 4th quarter worth $135,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.